Farber Disease Natural History Study

Sumitomo Pharma Switzerland GmbH45 enrolled

Overview

The primary objective of this study is to establish the natural history of Farber disease (acid ceramidase deficiency) through the collection and analysis of retrospective and prospective data on patients diagnosed with Farber disease. All patients diagnosed with Farber disease are eligible, including both those who have and have not undergone hematopoietic stem cell transplantation (HSCT). Additionally, data and records from deceased patients will provide valuable retrospective data for this study. The secondary objective of the study is to establish a set of clinical data, laboratory data (biomarkers), and functional data potentially useful for: * Assessing the efficacy of HSCT and the efficacy of potential future therapies (for example with RVT-801, recombinant human acid ceramidase) in Farber disease * Characterizing changes in symptoms of patients over time * Characterizing distinct groups (phenotypes) within the patient population * Documenting the disease histories of individual patients to serve as intra-subject control data for those who may enroll in any future clinical studies with therapies for Farber disease The exploratory objectives of the study are: * To explore the relationship between patient disease activity or phenotype and specific ceramide levels or specific immunologic markers (cytokines/chemokines) in blood * To evaluate a standardized tool, the Farber Disease Natural History Instrument (FDNI), to be used for the collection of patient history information, data from clinical, laboratory, genetic, and functional studies, and data from review of medical records

Study Type

OBSERVATIONAL

Enrollment

Conditions

Farber Disease Farber's Disease Farber Lipogranulomatosis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Living or deceased subjects with diagnosis of Farber disease, based on clinical (typical clinical symptoms) and biochemical and/or genetic criteria, as follows: * Biochemical: An acid ceramidase activity value in white blood cells, cultured skin fibroblasts or other biological sources (e.g., plasma) that is less than 30% of control (normal) values established by the testing laboratory. For deceased subjects only, storage of ceramide in cells from histopathologic sections is also adequate to confirm the diagnosis. * Genetic: Nucleotide changes within both alleles of the acid ceramidase gene (ASAH1) or cDNA that indicate, through bioinformatics, gene expression studies, or other methods, a possible loss of function of the acid ceramidase protein. * Informed consent or assent, for living subjects. For deceased subjects it is the responsibility of the principal investigator to ensure that the proper requirements are met according to local laws and regulations. Exclusion Criteria: • Current use or history of use in the past 30 days of an investigational agent (with exception of off-label use of medications).

Locations (15)

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States

Children's National Health System

Washington D.C., District of Columbia, United States

Hospital de Niños de la Santisima Trinidad

Córdoba, CP, Argentina

Montreal Children's Hospital

Montreal, Quebec, Canada

Cairo University

Cairo, Egypt

Universitätsklinikum Giessen, Zentrum für Kinderheilkunde und Jugendmedizin

Giessen, Hesse, Germany

Lok Nayak Hospital & Maulana Azad Medical College

Dehli, India

Sir Ganga Ram Hospital

Delhi, India

IRCCS Istituto Giannina Gaslini

Genoa, Italy

University of Milan

Milan, Italy

...and 5 more locations

Outcomes

Primary Outcomes

Establish a dataset on the natural history of Farber Disease

Collection of information for all subjects will include data from: * Medical history * Farber disease diagnosis, presentation, treatments and symptom progression Collection of information from living subjects will include: * Medical examination * Disease-specific data (Farber Disease Natural History Instrument - FDNI) * Laboratory tests (laboratory assessments and inflammatory markers) * Functional tests * Six-minute walk test (6MWT) * Pulmonary function testing * Additional assessments and evaluations: * Patient reported outcomes * Pain assessment * Relative impact of symptoms * Nodule Impact Questionnaire * Physician and Patient/Parent global assessment * Measurement and clinical characteristics of index nodules * Ultrasound evaluation of liver and spleen * High-frequency ultrasound

Time frame: Up to 21 months